SCHEMBL3982040

SCHEMBL3982040

CNC(=O)c1cccnc1Nc1cc(C(C)(C)C)nn1-c1cccc(F)c1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.45
POLB P06746 2/20 0.44
LMNA P02545 1/20 0.44
BRAF P15056 4/20 0.40
MAPK11 Q15759 4/20 0.40
MAPK14 Q16539 4/20 0.40
JAK1 P23458 4/20 0.40
RAF1 P04049 3/20 0.40
NTRK1 P04629 2/20 0.40
ABL1 P00519 2/20 0.40
JAK2 O60674 2/20 0.40
PLK4 O00444 1/20 0.40
ACOX3 O15254 1/20 0.40
MAP3K7 O43318 1/20 0.40
DYRK3 O43781 1/20 0.40
ERN1 O75460 1/20 0.40
RPS6KA4 O75676 1/20 0.40
STK10 O94804 1/20 0.40
MAP4K4 O95819 1/20 0.40
LCK P06239 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974547 0.87 MAPK14 (0.39) RIPK1BRAFMAPK11MAPK14JAK1
SCHEMBL3980491 0.86 RIPK1 (0.45) RIPK1POLBLMNABRAFMAPK11
SCHEMBL3973026 0.83 DHODH (0.44) LMNAMAPK11MAPK14MAPK13MAPK12
SCHEMBL3975037 0.81 MAPK13 (0.37) BRAFMAPK11MAPK14JAK1RAF1
SCHEMBL3974469 0.80 MAPK14 (0.46) RIPK1POLBLMNABRAFMAPK11
SCHEMBL3978605 0.79 DHODH (0.46) LMNAMAPK11MAPK14MAPK13MAPK12
SCHEMBL3976185 0.78 MEN1 (0.40) RIPK1POLBLMNABRAFMAPK11
SCHEMBL3975140 0.78 MAPK14 (0.41) BRAFMAPK11MAPK14RAF1NTRK1
SCHEMBL13752292 0.77 DHODH (0.51) BRAFMAPK11MAPK14MAPK13MAPK12
SCHEMBL3976410 0.74 LMNA (0.47) LMNAMAPK11MAPK14MAPK9DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes GPR119, GOT2, IAPP RIPK1 3316/4885POLB 3716/4885LMNA 3423/4885
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES GPR119, GOT2, IAPP RIPK1 3316/4885POLB 3716/4885LMNA 3423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.